-

Kincell Bio Expands Production With New Development and Manufacturing Partnership

New contract reinforces Kincell Bio’s commitment to long-term partnerships to address development and GMP manufacturing support for engineered cellular therapies.

DURHAM, N.C.--(BUSINESS WIRE)--Kincell Bio, a technology-forward cell therapy cGMP contract development and manufacturing organization (CDMO), today announced that it has welcomed a new partner for the production of early-phase clinical material of an allogeneic cell therapy product. This contract follows the acquisition of the GMP-ready facility in April 2024 and augments the manufacturing activities already occurring at the site. The agreement represents a multi-year relationship and strongly validates the team’s competency in allogeneic cell therapy production and release.

“Kincell Bio continues to build meaningful partnerships with our customers, providing critical CMC development and manufacturing expertise to support their clinical trials," said Bruce Thompson, PhD., CEO of Kincell Bio.

Share

The partner is a leading biotechnology company known for pioneering advancements in novel biologic medicines. This collaboration underscores our shared commitment to driving innovation in the development and manufacturing of cutting-edge therapies aimed at addressing unmet medical needs.

“Kincell Bio continues to build meaningful partnerships with our customers, providing critical CMC development and manufacturing expertise to support their clinical trials,” said Bruce Thompson, PhD., CEO of Kincell Bio. “Our entire team is energized to support innovative approaches that help bring new cellular therapies to market and help patients.”

This new contract exemplifies Kincell Bio's ongoing efforts to expand its portfolio of partnerships and enhance its manufacturing capabilities, reinforcing its position as a strong partner in the cell therapy CDMO space.

About Kincell Bio

Kincell Bio engineers cells into therapies. With manufacturing facilities located in Research Triangle Park, NC and Gainesville, FL, Kincell is a contract development and manufacturing organization (CDMO) situated in the Southeastern United States. Kincell Bio’s mission is to streamline CMC development, with expertise in analytical and process development and GMP manufacturing, testing and release. Kincell Bio is focused on supporting innovative companies developing immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programs. For more information, visit www.kincellbio.com.

Contacts

Business & Media Enquiries
Bruce Thompson, PhD
Chief Executive Officer
contactus@kincellbio.com

Industry:

Kincell Bio

Release Summary
New contract reinforces Kincell Bio’s commitment to long-term partnerships to address development and GMP manufacturing support for cellular therapies
Release Versions
English
Hashtags
#CDMO
#ClinicalDevelopment
#KincellBio
#celltherapy
#innovation
#lifesciences
#partnership

Contacts

Business & Media Enquiries
Bruce Thompson, PhD
Chief Executive Officer
contactus@kincellbio.com

Social Media Profiles
Kincell Bio on LinkedIn
More News From Kincell Bio

Kincell Bio Announces Collaboration to Advance Moonlight Bio’s Lead Cell Therapy Candidate to Clinical Study

DURHAM, N.C.--(BUSINESS WIRE)--Kincell Bio, a leading US cell therapy CDMO, is excited to announce a partnership with Moonlight Bio, Inc., a Seattle-based biotech company pioneering advanced T cell therapies for solid tumors. In this partnership, Kincell provides CMC development and GMP manufacturing services to advance Moonlight’s lead T cell therapy program into clinic trials. Under the agreement, Kincell is providing process and analytical transfer and GMP manufacturing services to support t...

Kincell Bio Announces Strategic Collaboration with Major Academic Medical Center to Advance Cell and Gene Therapy Innovation

DURHAM, N.C.--(BUSINESS WIRE)--Kincell Bio Inc., a cell therapy contract development and manufacturing organization, today announced the signing of a memorandum of understanding with the Duke University School of Medicine. The collaboration is designed to accelerate innovation in cell and gene therapy research, strengthen translational pathways, and support the development of scalable and efficient manufacturing solutions for advanced biologics. Under the agreement, Kincell Bio and Duke will jo...

NewSpring Capital and Kineticos Life Sciences Lead $22 Million Investment in Cell Therapy CDMO, Kincell Bio; Appoints Industry Veteran Pete Buzy to Board of Directors

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital through its dedicated healthcare strategy, NewSpring Healthcare, which invests in innovative companies in the lower-middle market that improve the delivery of healthcare or bend the cost curve through technology and human capital efficiencies. The round was also led by existing investor, Kineticos Life Sciences, an operationally focused private equ...
Back to Newsroom